In recent years, the number of medical spas, weight loss clinics and concierge offices where patients pay a membership fee to access doctors directly, often on the same day, has exploded. But while patients pay for these services out of pocket, providers often still rely on software built for traditional insurance-based care.
ENTan 18-month-old startup, claims to be solving one of the industry’s biggest technology bottlenecks by creating an e-prescribing platform (a digital tool for submitting and managing prescriptions) designed for cash-paying medical businesses.
On Wednesday, VITL announced a $7.5 million Series A funding round led by SignalFire.
Founder and CEO Charlie Jordan created the Nashville-based company after realizing how much time medical providers spend managing prescriptions for treatments that aren’t covered by insurance.
Many providers still rely on faxes or phone calls to send prescriptions to compounding pharmacies, which create custom medications to order, often without knowing the final cost to the patient or how long it will take to fill the order. VITL’s platform solves this problem by connecting clinics to a national network of compounding pharmacies, offering real-time price comparisons and Amazon-style order tracking.
“We shortened the prescription time from several minutes to a few seconds,” Jordan told TechCrunch.
For clinics that fill dozens of orders each day, that time savings adds up.
Technology event
San Francisco, CA
|
October 13-15, 2026
VITL estimates that its technology saves clients up to two full business days per month by automating an otherwise cumbersome and opaque process.
Cash payment providers are clearly seeing the value of VITL’s platform. Just over a year after launching, the company reports having added more than 630 clinics and generating eight figures in annualized recurring revenue (ARR), meaning the company is on track to generate at least $10 million per year.
That said, 630 customers represent just a fraction of a market that includes tens of thousands of clinics across the United States. As interest in GLP-1s (the class of drugs that includes Ozempic and Wegovy), peptides, and cosmetic procedures like Botox becomes more common, the number of healthcare businesses that pay cash will only increase.
VITL never launched SignalFire, but the startup’s rapid growth caught its attention. That interest translated into a new $7.5 million Series A led by the venture firm, which is known for using data and artificial intelligence to identify emerging companies.
VITL competes in part with Surescripts, the industry’s electronic prescribing pioneer, and with boutique clinical platforms such as Jane Software, which bundle prescribing functions into their broader electronic health record (EHR) software. What sets VITL apart from these competitors, he says, is its singular focus on the workflow requirements of the cash-based medical industry.
